You browser is out of date and some functionality on this site may be not supported.
Please consider upgrading to the latest version of your browser for the best possible experience.
Kindly note that this website is not compatible with this browser. Some features may not work. Inconvenience regretted.
In many countries screening for Glucose-6-Phosphate Dehydrogenase (G6PD) is a part of thenewborn screening program. In Indonesia the National Newborn screening program started in 2012 exclu-sively for Congenital Hypothyroidism and screening for G6PD has not been included in the National Screen-ing Program. Deﬁciency of G6PD can cause many manifestations with high morbidity rate. Different areasin Indonesia might have different proportion of G6PD deﬁciency. In Indonesia, there is no report on screen-ing for G6PD deﬁciencies in newborn babies. Objective: To estimate the prevalence of G6PD deﬁciencies inIndonesian newborn. Methodology: Dried blood spot (DBS) samples were collected from many provinces allover Indonesia as part of the National Screening Program for Hypothyroid, and 676 DBS samples receivedin May–June 2017 were analyzed for G6PD deﬁciency using LabSystem Neonatal G6PD kit and FluorometerThermo Scientiﬁc instrument. Results: From 676 newborn this study it was found that the G6PD deﬁciency wasobserved in 7.39 male and 6.95% female babies. The cutoff value for G6PD deﬁciency was less than 4,5 IU/gHb.The proportion was higher in males babies compared to females. Based on this ﬁnding, the G6PD screeningshould be performed in all newborn because the total prevalence was more than 3–5% as stated by the WHOrecommendationDownload